NO914003L - Fremgangsmaate for fremstilling av hydroxyalkylkinolinethersyrer som leukotrienantagonister - Google Patents

Fremgangsmaate for fremstilling av hydroxyalkylkinolinethersyrer som leukotrienantagonister

Info

Publication number
NO914003L
NO914003L NO91914003A NO914003A NO914003L NO 914003 L NO914003 L NO 914003L NO 91914003 A NO91914003 A NO 91914003A NO 914003 A NO914003 A NO 914003A NO 914003 L NO914003 L NO 914003L
Authority
NO
Norway
Prior art keywords
hydroxyalkylkinolinether
acids
procedure
preparation
antagonists
Prior art date
Application number
NO91914003A
Other languages
English (en)
Norwegian (no)
Other versions
NO914003D0 (no
Inventor
Michel L Belley
Yves Leblanc
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of NO914003D0 publication Critical patent/NO914003D0/no
Publication of NO914003L publication Critical patent/NO914003L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO91914003A 1990-10-12 1991-10-11 Fremgangsmaate for fremstilling av hydroxyalkylkinolinethersyrer som leukotrienantagonister NO914003L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59688590A 1990-10-12 1990-10-12

Publications (2)

Publication Number Publication Date
NO914003D0 NO914003D0 (no) 1991-10-11
NO914003L true NO914003L (no) 1992-04-13

Family

ID=24389130

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91914003A NO914003L (no) 1990-10-12 1991-10-11 Fremgangsmaate for fremstilling av hydroxyalkylkinolinethersyrer som leukotrienantagonister

Country Status (18)

Country Link
EP (1) EP0480708B1 (de)
JP (1) JP2538154B2 (de)
KR (1) KR920008005A (de)
CN (1) CN1061594A (de)
AT (1) ATE128969T1 (de)
AU (1) AU639612B2 (de)
CA (1) CA2053208C (de)
CS (1) CS309491A3 (de)
DE (1) DE69113735T2 (de)
ES (1) ES2079586T3 (de)
FI (1) FI914795A (de)
HU (1) HUT61982A (de)
IE (1) IE913610A1 (de)
IL (1) IL99683A0 (de)
MX (1) MX9101556A (de)
NO (1) NO914003L (de)
PT (1) PT99211B (de)
ZA (1) ZA918115B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506227A (en) * 1992-04-13 1996-04-09 Merck Frosst Canada, Inc. Pyridine-substituted benzyl alcohols as leukotriene antagonists
US5358955A (en) * 1992-10-30 1994-10-25 Abbott Laboratories Aryl and heteroarylmethoxyphenyl inhibitors of leukotriene biosynthesis
US5438141A (en) * 1993-05-21 1995-08-01 Merck Frosst Canada, Inc. Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
AU3868497A (en) * 1996-08-26 1998-03-19 Yamanouchi Pharmaceutical Co., Ltd. Benzenesulfone compounds and salts thereof
GB2356139A (en) * 1999-11-15 2001-05-16 Bayer Ag Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and cyanamides for the treatment of diseases
EP1958936A1 (de) * 2007-02-14 2008-08-20 Inke, S.A. Verfahren zur Gewinnung von Montelukast
BR112014001760A2 (pt) * 2011-07-26 2017-03-07 Sun Pharma Advanced Res Co Ltd antagonistas de leucotrieno cisteínico

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62120365A (ja) * 1985-11-16 1987-06-01 バイエル・アクチエンゲゼルシヤフト 置換ベンジルエ−テル類、その製造法および用途
IE59889B1 (en) * 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
JPS62258369A (ja) * 1986-05-02 1987-11-10 Nippon Soda Co Ltd キナゾリノン誘導体及びその製造方法
EP0271287A3 (de) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Chinolindicarbonsäuren und ihre Amide
IL88433A0 (en) * 1987-11-25 1989-06-30 Merck Frosst Canada Inc Diarylstyrylquinoline diacids and pharmaceutical compositions containing them
EP0349062A1 (de) * 1988-06-27 1990-01-03 Merck Frosst Canada Inc. Chinolinetheralkansäuren
NZ233752A (en) * 1989-05-24 1993-05-26 Merck Frosst Canada Inc Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
HUT61982A (en) 1993-03-29
CN1061594A (zh) 1992-06-03
MX9101556A (es) 1994-01-31
DE69113735D1 (de) 1995-11-16
JPH05105664A (ja) 1993-04-27
ES2079586T3 (es) 1996-01-16
NO914003D0 (no) 1991-10-11
CS309491A3 (en) 1992-04-15
PT99211B (pt) 1999-04-30
FI914795A0 (fi) 1991-10-11
EP0480708B1 (de) 1995-10-11
AU639612B2 (en) 1993-07-29
PT99211A (pt) 1992-09-30
CA2053208A1 (en) 1992-04-13
CA2053208C (en) 2003-04-15
EP0480708A3 (en) 1992-05-20
EP0480708A2 (de) 1992-04-15
ZA918115B (en) 1992-08-26
KR920008005A (ko) 1992-05-27
ATE128969T1 (de) 1995-10-15
JP2538154B2 (ja) 1996-09-25
IE913610A1 (en) 1992-04-22
DE69113735T2 (de) 1996-06-13
AU8579791A (en) 1992-04-16
HU913218D0 (en) 1992-01-28
IL99683A0 (en) 1992-08-18
FI914795A (fi) 1992-04-13

Similar Documents

Publication Publication Date Title
NO914004D0 (no) Fremgangsmaate for fremstilling av umettede hydroxyalkylkinolinsyrer
NO943792L (no) Kinolinderivater som leukotrienantagonister
NO920681L (no) Kinolinholdige ketosyrer som leukotrien-antagonister
NO914003L (no) Fremgangsmaate for fremstilling av hydroxyalkylkinolinethersyrer som leukotrienantagonister
NO952495D0 (no) Diaryl-5,6-kondenserte heterosykliske syrer som leukotrienantagonister